1063 related articles for article (PubMed ID: 27189322)
1. RECIST 1.1-Update and clarification: From the RECIST committee.
Schwartz LH; Litière S; de Vries E; Ford R; Gwyther S; Mandrekar S; Shankar L; Bogaerts J; Chen A; Dancey J; Hayes W; Hodi FS; Hoekstra OS; Huang EP; Lin N; Liu Y; Therasse P; Wolchok JD; Seymour L
Eur J Cancer; 2016 Jul; 62():132-7. PubMed ID: 27189322
[TBL] [Abstract][Full Text] [Related]
2. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eisenhauer EA; Therasse P; Bogaerts J; Schwartz LH; Sargent D; Ford R; Dancey J; Arbuck S; Gwyther S; Mooney M; Rubinstein L; Shankar L; Dodd L; Kaplan R; Lacombe D; Verweij J
Eur J Cancer; 2009 Jan; 45(2):228-47. PubMed ID: 19097774
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of lymph nodes with RECIST 1.1.
Schwartz LH; Bogaerts J; Ford R; Shankar L; Therasse P; Gwyther S; Eisenhauer EA
Eur J Cancer; 2009 Jan; 45(2):261-7. PubMed ID: 19091550
[TBL] [Abstract][Full Text] [Related]
4. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.
Schwartz LH; Seymour L; Litière S; Ford R; Gwyther S; Mandrekar S; Shankar L; Bogaerts J; Chen A; Dancey J; Hayes W; Hodi FS; Hoekstra OS; Huang EP; Lin N; Liu Y; Therasse P; Wolchok JD; de Vries E
Eur J Cancer; 2016 Jul; 62():138-45. PubMed ID: 27237360
[TBL] [Abstract][Full Text] [Related]
5. Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria.
Goebel J; Hoischen J; Gramsch C; Schemuth HP; Hoffmann AC; Umutlu L; Nassenstein K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2527-2533. PubMed ID: 28825135
[TBL] [Abstract][Full Text] [Related]
6. Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment.
Lai YC; Chang WC; Chen CB; Wang CL; Lin YF; Ho MM; Cheng CY; Huang PW; Hsu CW; Lin G
Acta Radiol; 2020 Jul; 61(7):983-991. PubMed ID: 31739675
[TBL] [Abstract][Full Text] [Related]
7. RECIST - learning from the past to build the future.
Litière S; Collette S; de Vries EG; Seymour L; Bogaerts J
Nat Rev Clin Oncol; 2017 Mar; 14(3):187-192. PubMed ID: 27995946
[TBL] [Abstract][Full Text] [Related]
8. CT Evaluation of Lymph Nodes That Merge or Split during the Course of a Clinical Trial: Limitations of RECIST 1.1.
Shafiei A; Bagheri M; Farhadi F; Apolo AB; Biassou NM; Folio LR; Jones EC; Summers RM
Radiol Imaging Cancer; 2021 May; 3(3):e200090. PubMed ID: 33874734
[TBL] [Abstract][Full Text] [Related]
9. RECIST revisited: a review of validation studies on tumour assessment.
Therasse P; Eisenhauer EA; Verweij J
Eur J Cancer; 2006 May; 42(8):1031-9. PubMed ID: 16616487
[TBL] [Abstract][Full Text] [Related]
10. Response evaluation criteria in solid tumours (RECIST): problems and need for modifications in paediatric oncology?
McHugh K; Kao S
Br J Radiol; 2003 Jul; 76(907):433-6. PubMed ID: 12857700
[No Abstract] [Full Text] [Related]
11. The minimum number of target lesions that need to be measured to be representative of the total number of target lesions (according to RECIST).
Darkeh MH; Suzuki C; Torkzad MR
Br J Radiol; 2009 Aug; 82(980):681-6. PubMed ID: 19366735
[TBL] [Abstract][Full Text] [Related]
12. Observer variability in RECIST-based tumour burden measurements: a meta-analysis.
Yoon SH; Kim KW; Goo JM; Kim DW; Hahn S
Eur J Cancer; 2016 Jan; 53():5-15. PubMed ID: 26687017
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review.
Kim JH; Kim BJ; Jang HJ; Kim HS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):729-735. PubMed ID: 28780726
[TBL] [Abstract][Full Text] [Related]
14. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
Watanabe H; Okada M; Kaji Y; Satouchi M; Sato Y; Yamabe Y; Onaya H; Endo M; Sone M; Arai Y
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2495-501. PubMed ID: 20009446
[TBL] [Abstract][Full Text] [Related]
15. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of RECIST 1.1 and iRECIST for Response Evaluation in Solid Tumours].
Houdek Š; Büchler T; Kindlová E
Klin Onkol; 2017; 30(Supplementum3):32-39. PubMed ID: 29239190
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review.
Min SJ; Jang HJ; Kim JH
Oncotarget; 2016 May; 7(19):27848-54. PubMed ID: 27036043
[TBL] [Abstract][Full Text] [Related]
18. Individual patient data analysis to assess modifications to the RECIST criteria.
Bogaerts J; Ford R; Sargent D; Schwartz LH; Rubinstein L; Lacombe D; Eisenhauer E; Verweij J; Therasse P;
Eur J Cancer; 2009 Jan; 45(2):248-60. PubMed ID: 19095437
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Sun JM; Ahn MJ; Park MJ; Yi JH; Kim TS; Chung MJ; Park YH; Ahn JS; Park K
Lung Cancer; 2010 Jul; 69(1):105-9. PubMed ID: 19959251
[TBL] [Abstract][Full Text] [Related]
20. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N;
Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
